Compass Therapeutics Inc. (CMPX) is scheduled to host a webcast on Tuesday, April 1, 2025, at 8:00 AM ET to review top-line clinical data from its ongoing COMPANION-002 clinical trial.
COMPANION-002 is a phase II/III trial evaluating the company's lead drug candidate Tovecimig plus paclitaxel against paclitaxel alone in patients with previously treated, unresectable advanced Metastatic or Recurrent Biliary Tract Cancers. This study completed enrollment of the planned 150 patients last August.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com